Ensifentrine: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 45 patientsc19early.org

Ensifentrine for COVID-19

Serious outcome risk
Ensifentrine
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−150%
Mortality (1)−150%
RCTs (1)−150%
Late (1)−150%
00.511.5+
← Ensifentrine
reduces riskIncreased
risk →
c19early.org
October 2026

Ensifentrine COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
MacDonal.. (DB RCT)−150%2.50 · 0.11–57.95death1/300/15
Late treatment−150%2.50 · 0.11–57.951/300/15150% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.58
All studies−150%2.50 · 0.11–57.951/300/15150% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+
Rotate screen for more detailsIncrease width for more details
← Ensifentrine
reduces riskEnsifentrine
increases risk →
c19early.org
October 2026

Ensifentrine COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
MacDonal.. (DB RCT)−150%2.50 · 0.11–57.951/300/15
Late treatment−150%2.50 · 0.11–57.951/300/15150% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.58
All studies−150%2.50 · 0.11–57.951/300/15150% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+
Rotate screen for more detailsIncrease width for more details
← Ensifentrine
reduces riskEnsifentrine
increases risk →
c19early.org
October 2026

Ensifentrine COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
MacDonal.. (DB RCT)−150%2.50 · 0.11–57.95death1/300/15
Late treatment−150%2.50 · 0.11–57.951/300/15150% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.58
All studies−150%2.50 · 0.11–57.951/300/15150% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+
Rotate screen for more detailsIncrease width for more details
← Ensifentrine
reduces riskEnsifentrine
increases risk →
c19early.org
October 2026

Ensifentrine COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
MacDonal.. (DB RCT)−150%2.50 · 0.11–57.95no recov.1/300/15
Late treatment−150%2.50 · 0.11–57.951/300/15150% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.58
All studies−150%2.50 · 0.11–57.951/300/15150% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+
Rotate screen for more detailsIncrease width for more details
← Ensifentrine
reduces riskEnsifentrine
increases risk →
c19early.org
October 2026

Ensifentrine COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
MacDonal.. (DB RCT)−150%2.50 · 0.11–57.95death1/300/15
Late treatment−150%2.50 · 0.11–57.951/300/15150% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.58
All studies−150%2.50 · 0.11–57.951/300/15150% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+
Rotate screen for more detailsIncrease width for more details
← Ensifentrine
reduces riskEnsifentrine
increases risk →
c19early.org
October 2026

Ensifentrine COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
MacDonal.. (DB RCT)−150%2.50 · 0.11–57.951/300/15
Late treatment−150%2.50 · 0.11–57.951/300/15150% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.58
All studies−150%2.50 · 0.11–57.951/300/15150% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+
Rotate screen for more detailsIncrease width for more details
← Ensifentrine
reduces riskEnsifentrine
increases risk →